InflaRx N.V. (IFRX) vs Keros Therapeutics (KROS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Keros Therapeutics (KROS) over the past year, gaining 13.0% versus a loss of 28.4%. Over five years, IFRX leads with a -36.8% price change compared with -71.2% for KROS. Keros Therapeutics is the larger company by market cap ($231.0 million vs $219.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | KROS |
|---|---|---|
| Share price | $1.49 | $11.65 |
| Market cap | $219.58M | $230.99M |
| 1-day change | -4.48% | +3.93% |
| YTD return | +54.46% | -44.94% |
| 1-year return | +13.04% | -28.37% |
| 5-year return | -36.84% | -71.25% |
| EPS (TTM) | $-0.58 | $-3.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $22.55 |
| 52-week low | $0.798 | $9.69 |
| Distance from 52-week high | -49.47% | -48.34% |
| Analyst consensus | none | buy |
| Avg. price target upside | +414.09% | +70.21% |
| Average volume | 794.10K | 196.01K |
| Shares outstanding | 147.37M | 19.83M |
| Employees | 65 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed KROS by 41.4 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
IFRX vs KROS FAQ
Which is bigger, InflaRx N.V. or Keros Therapeutics?
Keros Therapeutics (KROS) is larger, with a market capitalization of $230.99M compared with $219.58M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, IFRX or KROS?
IFRX returned +13.04% over the past 12 months, compared with -28.37% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Keros Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.